New Novo Nordisk drug could beat market leaders for weight loss, early results show
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Related reading
New Novo drug delivers significant weight-loss benefits in diabetes trial
Amycretin also improved participants’ blood sugar levels in positive sign for Danish company’s treatment pipeline
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
Novo Nordisk weight-loss drug wins US approval as a daily pill
Shares in Danish company rise as drugmaker secures lead in oral obesity treatment
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly